292 results on '"Mann, Helen"'
Search Results
52. Disentangling human TRPV1 polymodal activation and mechanisms
53. The road user behaviour of New Zealand adolescents
54. Abstract 489: Association between immune-mediated adverse events and survival in patients with metastatic non-small cell lung cancer treated with durvalumab and tremelimumab
55. Soft matter affects G-protein-coupled receptor activation
56. A national census of forensic in‐patients with intellectual disability and five‐year follow‐up.
57. Effects of Soft Matter on G-Protein-Coupled Receptor Activation
58. Driving in Parkinson’s disease: a retrospective study of driving and mobility assessments
59. Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
60. Modulation of GPCR Function by Membrane Lipids and Water
61. Additional file 1 of The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer
62. Modulation of GPCR Function by Membrane Lipids and Water
63. Epidermal Growth Factor Receptor Immunohistochemistry: Comparison of Antibodies and Cutoff Points to Predict Benefit From Gefitinib in A Phase 3 Placebo-Controlled Study in Advanced Nonsmall-Cell Lung Cancer
64. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
65. Soft Matter Control of GPCR Function by Membrane Lipids and Water
66. Water and Membrane Lipids Govern G-Protein Activation
67. EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
68. Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR‐Mutated Non–Small Cell Lung Cancer
69. Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies
70. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
71. Outcomes of expedited rotator cuff surgery in injured workers: Impact of pathology on readiness for return to work
72. Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The AURA3 Trial
73. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
74. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
75. Effectiveness of a Multidisciplinary Rehabilitation Program Following Shoulder Injury
76. Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
77. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
78. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
79. Measurement of endrin following epidemics of poisoning
80. Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression ≥25%: Results from the Randomized Phase 3 PEARL Study
81. Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
82. Abstract B105: Characterization of the activity of AZD9291 in patients (pts) with T790M ‘negative’ advanced non-small cell lung cancer (aNSCLC)
83. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
84. Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.
85. Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
86. POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2mutation (gBRCAm) who have not progressed following first-line chemotherapy.
87. Abstract OT1-1-04: OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
88. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
89. Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).
90. Utility values in health technology assessments: a statistician's perspective
91. Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals
92. Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).
93. Abstract LB-146: A phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME).
94. Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity
95. Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours
96. Abstract C9: Utility of serological apoptosis biomarkers: Assessment in a phase II study of zibotentan (ZD4054) in patients with hormone‐resistant prostate cancer
97. Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer
98. Family carers of stroke survivors: needs, knowledge, satisfaction and competence in caring
99. Study design and rationale for a randomised, placebo-controlled, doubleblind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
100. Book Reviews
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.